The NK-92 cell line has become a very relevant tool for natural killer (NK) cell research, largely because it largely mirrors the characteristics of human blood-derived NK cells. It also has a doubling time of less than 30 h, making it possible to generate a significant number of cells in a relatively short time. Its safety as an anti-cancer cell therapy has been documented in over 200 cancer patients. Various genetically engineered variants have been generated that express a high-affinity Fc-receptor and various chimeric antigen receptors (CARs) and secrete immune-active cytokines. NK-92 cells expressing CARs for HER-2, PD-L1, and CD19 CAR are in advanced clinical trials in cancer patients. These cells also have cytotoxic activity against targets infected with bacteria, fungi, and viruses. More recently, the cellular lysate of NK-92 cells, generated by simple freeze/thaw, has shown anti-cancer potential when injected intra-tumor. Since a comprehensive review of NK-92 was recently published on the occasion of its 30-year “anniversary”, this review will focus on more recent research initiatives and results with the cell line.
NK-92细胞系已成为自然杀伤（NK）细胞研究中极为重要的工具，主要因其高度模拟人外周血来源NK细胞的特性。该细胞系倍增时间不足30小时，可在较短时间内获得大量细胞。其作为抗癌细胞疗法的安全性已在200多名癌症患者中得到验证。目前通过基因工程改造已构建出多种变体，这些变体能够表达高亲和力Fc受体及多种嵌合抗原受体（CAR），并分泌免疫活性细胞因子。针对HER-2、PD-L1和CD19的CAR-NK-92细胞已在癌症患者中进入高级临床试验阶段。该细胞系对细菌、真菌和病毒感染的靶标同样具有细胞毒活性。最新研究表明，通过简单冻融法制备的NK-92细胞裂解物在瘤内注射时显示出抗癌潜力。鉴于近期已有文献在其问世30周年之际对NK-92进行了全面综述，本文将聚焦于该细胞系的最新研究进展与成果。
肿瘤(癌症)患者之家